AI-Driven Early Detection of Skin Cancer
ConditionSkin Cancer Melanoma
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorNuvana Healthcare LTD
About this trial
This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.
Eligibility criteria
Qualifiers
None
Disqualifiers
None
Trial design
Treatments tested in this trial
- Smartphone-based AI skin lesion analysis (NuvanaDx platform).
Treatment groups
100 Participants
are divided into 1 treatment groupSponsors and collaborators
Nuvana Healthcare LTD
Lead sponsor
National Institute for Health Research, United Kingdom
Collaborator
Source ClinicalTrials.gov